The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report
J. Anderson, Jordan Schauer, Suzanne Bryant, Cornelia Graves
Abstract
Remdesivir is a novel therapeutic with known activity against SARS CoV-2 and related coronaviruses. Remdesivir, as well as convalescent plasma therapy, are currently under investigation as potential therapies for patients with Coronavirus Disease 19 (COVID-19). In this case report we summarize the use of convalescent plasma therapy and then remdesivir as a late addition in the treatment of a critically ill obstetric patient with COVID-19. The patient subsequently improved, was extubated 5 days after initiation of remdesivir, was transitioned to room air 24 h later, and discharged at the completion of remdesivir therapy.
Topics & Concepts
MedicineConvalescent plasmaCoronavirus disease 2019 (COVID-19)CoronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Intensive care medicineCritically ill2019-20 coronavirus outbreakDiseaseVirologyInternal medicineInfectious disease (medical specialty)OutbreakCOVID-19 Impact on ReproductionCOVID-19 Clinical Research StudiesCOVID-19 and Mental Health